Panacea Biotec says ANDA of Prasugrel approved by US FDA
The company is also entitled for 180 days of shared market exclusivity for the Prasugrel HCL tablets,24-10-2017
24-10-2017
Press Release / Media Release
Panacea Biotec Limited is pleased to announce that its first-to-file ANDA of Prasugrel 5mg and 10mg tablets has been approved by the United States Food & Drug Administration (U.S.FDA). Under the provisions of Hatch-Waxman Act, the Company is entitled for 180-days of shared marketing exclusivity for Prasugrel HCL tablets with this final FDA approval24-10-2017
Press Release / Media Release
Panacea Biotec Ltd. is pleased to announce that it has received the Certificate of GMP Compliance from State Service of Ukraine on Medicines and Drugs Control with manufacturing authorization for 22 medicinal products, including 4 oncology products valid till June 24, 2020.17-10-2017
Panacea Biotec rallies 13% as 22 products gets GMP compliance in Ukraine
The stock up 13% to Rs 255 after the company gets certificate of GMP compliance with manufacturing authorization for 22 medicinal products from state service of Ukraine on medicines & drugs control.17-10-2017
Shareholding for the Period Ended September 30, 2017
Panacea Biotec Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2017. For more details, kindly Click here12-10-2017
Compliance Certificate Under Regulation 7(3) Of The SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 For The Half-Year Ended On 30Th September, 2017
Compliance Certificate under Regulation 7(3) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 for the half-year ended on 30th September, 201706-10-2017
Pursuant To Regulation 13(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, Quarterly Report Towards Investor Grievance For The Quarter Ended September 30, 2017
Quarterly report of Investor Complaints under Regulation 13 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter ending September 30, 201706-10-2017
Annual Report Of Panacea Biotec Limited For The Financial Year 2016-17
Pursuant to the provisions of Regulation 34(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the soft copy of Annual Report of the Company for the financial year 2016-17 containing the Audited Financial Statements of the Company for the financial year ended March 31, 2017 together with the reports of the Board of Directors and the Auditors thereon, duly approved and adopted at the 33rd Annual General Meeting of...05-10-2017
Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Panacea Biotec Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here29-09-2017
Outcome of AGM
This is in continuation of our earlier letter dated September 28, 2017 informing that the detailed results of remote e-voting and the poll conducted at the Annual General Meeting ('AGM') of the Company held on September 27, 2017, as required under Regulation 44 of the SEBI Listing Regulations shall be forwarded to you on the receipt of Scrutinizer's Report....29-09-2017